CN101379183B - 流感病毒的拯救 - Google Patents

流感病毒的拯救 Download PDF

Info

Publication number
CN101379183B
CN101379183B CN2005800447512A CN200580044751A CN101379183B CN 101379183 B CN101379183 B CN 101379183B CN 2005800447512 A CN2005800447512 A CN 2005800447512A CN 200580044751 A CN200580044751 A CN 200580044751A CN 101379183 B CN101379183 B CN 101379183B
Authority
CN
China
Prior art keywords
influenza
virus
cells
polymerase
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800447512A
Other languages
English (en)
Chinese (zh)
Other versions
CN101379183A (zh
Inventor
E·德维特
M·I·J·斯普隆肯
R·A·M·福切尔
A·D·M·E·奥斯特霍斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Solva Biology Co Ltd
Erasmus University Medical Center
Original Assignee
Erasmus University Medical Center
Abbott Biologicals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus University Medical Center, Abbott Biologicals BV filed Critical Erasmus University Medical Center
Publication of CN101379183A publication Critical patent/CN101379183A/zh
Application granted granted Critical
Publication of CN101379183B publication Critical patent/CN101379183B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18651—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2005800447512A 2004-12-24 2005-12-22 流感病毒的拯救 Expired - Fee Related CN101379183B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04078527 2004-12-24
EP04078527.1 2004-12-24
PCT/EP2005/057092 WO2006067211A1 (en) 2004-12-24 2005-12-22 Rescue of influenza virus

Publications (2)

Publication Number Publication Date
CN101379183A CN101379183A (zh) 2009-03-04
CN101379183B true CN101379183B (zh) 2013-07-03

Family

ID=34928779

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800447512A Expired - Fee Related CN101379183B (zh) 2004-12-24 2005-12-22 流感病毒的拯救

Country Status (19)

Country Link
US (2) US7959930B2 (cg-RX-API-DMAC7.html)
EP (2) EP2295542B1 (cg-RX-API-DMAC7.html)
JP (2) JP5620048B2 (cg-RX-API-DMAC7.html)
KR (1) KR101272487B1 (cg-RX-API-DMAC7.html)
CN (1) CN101379183B (cg-RX-API-DMAC7.html)
AU (1) AU2005318087B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0518568A2 (cg-RX-API-DMAC7.html)
CA (1) CA2592439C (cg-RX-API-DMAC7.html)
DK (1) DK1831357T3 (cg-RX-API-DMAC7.html)
ES (1) ES2395813T3 (cg-RX-API-DMAC7.html)
IL (1) IL183888A (cg-RX-API-DMAC7.html)
MX (1) MX2007007889A (cg-RX-API-DMAC7.html)
NO (1) NO20073737L (cg-RX-API-DMAC7.html)
NZ (1) NZ556061A (cg-RX-API-DMAC7.html)
PT (1) PT1831357E (cg-RX-API-DMAC7.html)
RU (2) RU2435855C2 (cg-RX-API-DMAC7.html)
TW (2) TWI495724B (cg-RX-API-DMAC7.html)
WO (1) WO2006067211A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200705145B (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101921732A (zh) 2001-01-19 2010-12-22 维洛诺瓦蒂夫公司 在易感哺乳动物中引起呼吸道疾病的病毒
IL163646A0 (en) 2002-02-21 2005-12-18 Vironovative Bv Recombinant parainfluenza virus expression systemsand vaccines comprising heterologous antigens derived from metapneumovirus
JP5620048B2 (ja) * 2004-12-24 2014-11-05 アボツト・バイオロジカルズ・ベー・ブイＡｂｂｏｔｔ Ｂｉｏｌｏｇｉｃａｌｓ Ｂ．Ｖ． インフルエンザウイルスの救済（ｒｅｓｃｕｅ）
CA2613283A1 (en) 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing a heterologous protease
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
NZ567978A (en) 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
BRPI0618254A2 (pt) 2005-11-04 2011-08-23 Novartis Vaccines & Diagnostic emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido
EP3714900A1 (en) 2005-11-04 2020-09-30 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US20110180430A1 (en) 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
EP2368573A3 (en) 2005-11-04 2013-05-01 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
BR122019013216B8 (pt) 2006-01-27 2021-07-27 Seqirus Uk Ltd ensaio imunológico para análise de uma vacina contra influenza
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EA200970271A1 (ru) 2006-09-11 2010-02-26 Новартис Аг Получение вакцин против вируса гриппа без использования куриных эмбрионов
SG177141A1 (en) 2006-12-06 2012-01-30 Novartis Ag Vaccines including antigen from four strains of influenza virus
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
ES2393162T3 (es) 2007-06-27 2012-12-19 Novartis Ag Vacunas antigripales con un contenido reducido de aditivos
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
ES2535101T3 (es) 2008-03-18 2015-05-05 Novartis Ag Mejoras en la preparación de antígenos en vacuna de virus de la gripe
JP2012517416A (ja) 2009-02-10 2012-08-02 ノバルティス アーゲー 増加した量のｈ３抗原を含むインフルエンザワクチン
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
AU2010212547B2 (en) 2009-02-10 2015-03-12 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
CN102548577A (zh) 2009-04-27 2012-07-04 诺华有限公司 用于抵抗流感的佐剂疫苗
CN104862335A (zh) 2009-07-31 2015-08-26 诺华股份有限公司 反向遗传系统
ES2813347T3 (es) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US20130183740A1 (en) * 2010-06-02 2013-07-18 Avir Green Hills Biotechnology Research Development Trade Ag Novel method for generation of rna virus
FR2962739B1 (fr) * 2010-07-13 2014-01-31 Univ Claude Bernard Lyon Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza
EP2747778B1 (en) 2011-08-26 2017-12-06 Wisconsin Alumni Research Foundation Influenza viruses with mutant pb2 gene segment as live attenuated vaccines
CA2852857A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
US10080794B2 (en) 2013-03-15 2018-09-25 University Of Maryland, College Park Swine influenza viruses and constructs and uses thereof
AU2014290203B2 (en) 2013-07-15 2020-12-24 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
AU2016274770B2 (en) 2015-06-09 2020-11-12 Sanofi Pasteur, Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
HUE060924T2 (hu) 2015-07-07 2023-04-28 Seqirus Uk Ltd Influenza elleni hatásosság vizsgálata
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
WO2020033527A2 (en) 2018-08-07 2020-02-13 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
WO2020041311A1 (en) 2018-08-20 2020-02-27 Wisconsin Alumni Research Foundation Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003552A1 (en) * 1989-08-28 1991-03-21 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression systems and vaccines

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854037A (en) * 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US6001634A (en) * 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US6887699B1 (en) * 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
US6544785B1 (en) * 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
DE122008000058I1 (de) 1999-04-06 2009-05-07 Wisconsin Alumni Res Found Rekombinante influenzaviren zur vakzinherstellung und gentherapie
US8715940B2 (en) * 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
DE122007000061I2 (de) 1999-07-14 2011-07-21 Sinai School Medicine In vitro-rekonstitution von segmentierten negativstrang-rna-viren.
WO2001009309A2 (en) * 1999-08-02 2001-02-08 American Home Products Corporation RESCUE OF MUMPS VIRUS FROM cDNA
US6764685B1 (en) * 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
CN100489107C (zh) 2000-04-28 2009-05-20 圣朱德儿童研究医院 用于产生感染性流感病毒的dna转染系统
CA2410284A1 (en) * 2000-06-23 2002-01-03 American Cyanamid Company Nucleotide sequence of influenza a/udorn/72 (h3n2) genome
IL163646A0 (en) * 2002-02-21 2005-12-18 Vironovative Bv Recombinant parainfluenza virus expression systemsand vaccines comprising heterologous antigens derived from metapneumovirus
CN103540568A (zh) * 2002-04-26 2014-01-29 米迪缪尼有限公司 制备流感病毒的多质粒系统
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
JP5620048B2 (ja) * 2004-12-24 2014-11-05 アボツト・バイオロジカルズ・ベー・ブイＡｂｂｏｔｔ Ｂｉｏｌｏｇｉｃａｌｓ Ｂ．Ｖ． インフルエンザウイルスの救済（ｒｅｓｃｕｅ）

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003552A1 (en) * 1989-08-28 1991-03-21 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression systems and vaccines

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Emmie de Wit et al.Efficient generation and growth of influenza virus A/P/8/34 from eight cDNA fragments.《Virus Research》.2004,第103卷(第1-2期),全文. *
Erich Hoffmann et al."Ambisense"approach for the generation of influenza a virus：vRNA and mRNA synthesis from one template.《Virology》.2000,第267卷(第2期),全文.
Erich Hoffmann et al."Ambisense"approach for the generation of influenza a virus:vRNA and mRNA synthesis from one template.《Virology》.2000,第267卷(第2期),全文. *
Sean P.J. Whelan et al.Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones.《Proc.Natl.Acad.Sci》.1995,第91卷全文. *
刘玉良等.RNA 病毒"拯救"技术.《中国生物工程杂志》.2003,第23卷(第9期),全文.
黄耀伟等.人类及动物RNA 病毒的反向遗传系统.《生物工程学报》.2004,第20卷(第3期),全文. *

Also Published As

Publication number Publication date
US20080050401A1 (en) 2008-02-28
PT1831357E (pt) 2012-12-17
JP2008525003A (ja) 2008-07-17
NZ556061A (en) 2009-06-26
MX2007007889A (es) 2008-01-22
AU2005318087A1 (en) 2006-06-29
IL183888A (en) 2013-05-30
KR20070110838A (ko) 2007-11-20
KR101272487B1 (ko) 2013-06-07
BRPI0518568A2 (pt) 2008-11-25
RU2435855C2 (ru) 2011-12-10
RU2011122117A (ru) 2012-12-10
CA2592439C (en) 2014-06-03
RU2007128336A (ru) 2009-01-27
JP5702321B2 (ja) 2015-04-15
EP2295542B1 (en) 2013-01-30
CN101379183A (zh) 2009-03-04
TW201235472A (en) 2012-09-01
TWI402344B (zh) 2013-07-21
NO20073737L (no) 2007-09-21
AU2005318087B2 (en) 2011-04-21
JP5620048B2 (ja) 2014-11-05
ES2395813T3 (es) 2013-02-15
EP1831357B1 (en) 2012-10-17
JP2012147789A (ja) 2012-08-09
HK1125674A1 (en) 2009-08-14
TWI495724B (zh) 2015-08-11
EP1831357A1 (en) 2007-09-12
EP2295542A1 (en) 2011-03-16
CA2592439A1 (en) 2006-06-29
ZA200705145B (en) 2009-09-30
DK1831357T3 (da) 2012-12-10
IL183888A0 (en) 2007-10-31
WO2006067211A1 (en) 2006-06-29
US7959930B2 (en) 2011-06-14
US20120156241A1 (en) 2012-06-21
TW200636070A (en) 2006-10-16

Similar Documents

Publication Publication Date Title
CN101379183B (zh) 流感病毒的拯救
JP6352974B2 (ja) ワクチンのための高力価組み換えインフルエンザ・ウィルス
US11180737B2 (en) Generation of infectious influenza viruses from virus-like particles
EP2272950A2 (en) Defective influenza virus particles
JP2017197555A (ja) 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
WO2008147496A2 (en) Neuraminidase-deficient live influenza vaccines
AU2011204881B2 (en) Rescue of influenza virus
HK1153237A (en) Rescue of influenza virus
HK1125674B (zh) 流感病毒的拯救
CN102586199A (zh) 有缺陷的流感病毒颗粒
HK1171047A (en) Defective influenza virus particles
HK1153225A (en) Defective influenza virus particles

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1125674

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: SOLVAN BIOLOGY CO., LTD.

Free format text: FORMER OWNER: SOLVAY PHARMA GMBH

Effective date: 20090821

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20090821

Address after: Holland Weesp

Applicant after: Solva biology Co., Ltd.

Co-applicant after: Univ Erasmus Medical Ct

Address before: Holland Weesp

Applicant before: The drug Co., Ltd.

Co-applicant before: Univ Erasmus Medical Ct

C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Holland Weesp

Applicant after: Abbott Biologicals B.V.

Applicant after: Univ Erasmus Medical Ct

Address before: Holland Weesp

Applicant before: Solvay Pharm BV

Applicant before: Univ Erasmus Medical Ct

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: SOLVAY PHARM BV TO: ABBOTT BIOLOGY CO., LTD.

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1125674

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130703

Termination date: 20161222

CF01 Termination of patent right due to non-payment of annual fee